Matulane

(Procarbazine)

Phase 3Small molecule

LLeadiant Biosciences, Inc.

Matulane is one of 104 small molecule programs targeting Efficacy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

103

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

EfficacyActive, not recruiting

LymphomaCompleted

Low Grade GliomaActive, not recruiting

EfficacyPhase 1

Active, not recruiting

LymphomaPhase 3

Completed

Low Grade GliomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Matulane

LLeadiant Biosciences, Inc.

Phase 3

9 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Active, not recruiting

Efficacy

NCT06541665

Q4 2028

Phase 2Recruiting

Lymphoma

NCT07015242

Q4 2029

Phase 3Active, not recruiting

Low Grade Glioma

NCT00887146

Clinical

Trials by Indication[1]

Lymphoma9 trials

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05008224·146 enrolled

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT03495960·72 enrolled

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00577993·210 enrolled

Show 6 more trials

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT01569204·100 enrolled

Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma

Unknown status·UUniversity Hospital Freiburg·Phase 2·NCT00989352·56 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01390584·6 enrolled

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·NCT07015242·65 enrolled

Central Nervous System Lymphoma3 trials

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00335140·26 enrolled

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02315326·93 enrolled

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT01399372·91 enrolled

Advanced Stage2 trials

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

HD21 for Advanced Stages

Active, not recruiting·UUniversity of Cologne·Phase 3·NCT02661503·1,500 enrolled

Age1 trial

HD11 for Intermediate Stages

Completed·UUniversity of Cologne·Phase 3·NCT00264953·1,395 enrolled

Efficacy1 trial

Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06541665·20 enrolled

2 more indications

Low Grade Glioma1 trial

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00887146·305 enrolled

Brentuximab Vedotin1 trial

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02298283·40 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

MATULANE

NDA NDA016785

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Procarbazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Procarbazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Procarbazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA016785). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Leadiant Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLeadiant Biosciences, Inc.

Matulane

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Lymphoma9 trials

Central Nervous System Lymphoma3 trials

Advanced Stage2 trials

Age1 trial

Efficacy1 trial

Low Grade Glioma1 trial

Brentuximab Vedotin1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News